Less than two months after its unveiling, President Donald Trump’s plan to lower prescription drug prices is up for a big test. Investors aren’t particularly worried since it stopped short of calling for Medicare to directly negotiate prices with individual drug companies. What is more, the Trump administration has been rolling the plan out at a deliberate pace.
But there is a chance that prevailing attitude will soon change. Midterm elections loom in November. More immediately, July is a popular month for drug companies to increase list prices of their medicines.
